(AOF) – Medesis Pharma announces that its cash flow as of June 30, 2023 amounts to 139,000 euros, which gives it visibility “until the end of November 2023”. The biotech company posted a net loss of 1.61 million euros in the first half compared to 1.57 million a year ago, without having recorded any turnover. “Contacts are underway for capital contributions at the beginning of December and to move towards the establishment of licensing partnerships,” she announces.
This would involve collecting funding “in particular with regard to the progress of its clinical study on NanoLithium in the treatment of Alzheimer’s disease”.
Medesis Pharma recalls that it “requested and obtained the opening, on September 29, 2023, of a safeguard procedure” with the Montpellier Commercial Court. This procedure “can last up to twelve months” and aims to “provide a framework which makes it possible to overcome the difficulties encountered” in the context of its dispute with Bpifrance.
© 2023 Agence Option Finance (AOF) – All reproduction rights reserved by AOF. AOF collects its data from the sources it considers the safest. However, the reader remains solely responsible for their interpretation and use of the information made available to them. The reader must therefore hold AOF and its contributors harmless from any claim resulting from this use. Agence Option Finance (AOF) is a brand of the Option Finance group
Did you like this article ? Share it with your friends using the buttons below.
